Table IV.
Evidence for prostate cancer-targeting strategies of adenoviral mutants.
| Author, year | Therapeutic type | Mutational pattern | Therapeutic genes | Adenovirus | Combination | Experiment type | Result | (Refs.) |
|---|---|---|---|---|---|---|---|---|
| Cody et al, 2013 | Virotherapy | A 24-bp deletion in the E1A conserved region 2,Δ24 | OPG | Ad5-Δ24-sOPG-Fc-RGD | NA | In vitro/vivo | Specific inhibition of progression of prostate cancer bone metastases | (102) |
| Hakkarainen et al, 2009 | Virotherapy | A 24-bp deletion in the E1A conserved region 2,Δ24 | NIS | Ad5/3-∆24-hNIS | Radioiodine therapy | In vitro/vivo | Specific inhibition of prostate cancer/cells | (108) |
| Mao et al, 2015 | Virotherapy | Deletion of E1B-55K | shRNA targeting SATB1 | ZD55-SATB1 | NA | In vitro/vivo | Specific inhibition of prostate cancer growth and metastasis | (114) |
| Ding et al, 2012 | Virotherapy | Deletion of E1B-55K | PTEN | Ad.DD3.D55-PTEN | NA | In vitro/vivo | Specific inhibition of tumor/tumor cell growth | (115) |
| Radhakrishnan et al, 2010 | Virotherapy | Deletion of E3B/a 24-bp deletion in the E1A conserved region 2,Δ24 | NA | Ad-Δ55KΔE3B | Mitoxantrone/docetaxel | In vitro/vivo | Specific inhibition of androgen-independent prostate cancer/cells | (116) |
| Oberg et al, 2010 | Virotherapy | Deletion of E1B-19K/a 24-bp deletion in the E1A conserved region 2,Δ24 | NA | Ad-ΔCR2Δ19K | Mitoxantrone/docetaxel | In vitro/vivo | Specific inhibition of androgen-independent prostate cancer/cells | (117) |
| Satoh et al, 2007 | Virotherapy | Deletion of E1B-55K/a 24-bp deletion in the E1A conserved region 2,Δ24 | NA | AxdAdB-3 | NA | In vitro/vivo | Specific inhibition of androgen-independent prostate cancer/cells | (118) |
OPG, osteoprotegerin; NA, not applicable; NIS, sodium iodide symporter; −55/19K, −55/19 kDa; shRNA, short hairpin RNA; SATB homeobox 1; PTEN, phosphatase and tensin homolog.